<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143217</url>
  </required_header>
  <id_info>
    <org_study_id>812P311</org_study_id>
    <nct_id>NCT04143217</nct_id>
  </id_info>
  <brief_title>Open-label Study to Evaluate Long-Term Safety and Efficacy of SPN-812 in Adults With ADHD</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supernus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supernus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in
      adult ADHD patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label extension study aimed to assess long-term safety and
      efficacy of SPN-812 when administered alone or in conjunction with an Food and Drug
      Administration-approved Attention Deficit Hyperactivity Disorder (ADHD) medication in the
      treatment of ADHD in adult subjects who have participated in a previous blinded study of
      SPN-812 (812P306). All adult subjects who completed the blinded study of SPN-812 will have
      the option to participate in this study in which all subjects receive SPN-812 at an optimized
      dose. Subjects will initiate SPN-812 dosing at 200 mg/day once daily (QD) for 1 week, then
      titrate to 400 mg/day at start of Week 2. It is recommended that subjects remain on 400
      mg/day during Week 3. At or after Visit 3 (Week 4), per the Investigator's discretion and
      based on Investigator assessment of the subject's clinical response and tolerability, the
      dose of SPN-812 can be titrated up or tapered down in increments of 50 mg/day, 100 mg/day,
      150 mg/day, or 200 mg/day per week to a target dose within the ranges between 200 and 600
      mg/day. Additionally, after 3 months of dosing (after Visit 4), at the discretion of the
      Investigator and based on the subject's clinical response, the optimized dose of SPN-812 may
      be supplemented with an adjunctive FDA-approved stimulant treatment. The total study duration
      per subject from Visit 1 to the EOS (Visit 9) will be ~52 weeks or until SPN-812 becomes
      commercially available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open Label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>2 weeks - 4 weeks</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD symptoms as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of severity as measured by the Clinical Global Impression - Severity of Illness (CGI-S) scale for ADHD</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in CGI-S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate of severity of illness as measured by the categorical CGI-S Responder Rate (CGI-S score of 1 or 2)</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Percentage of subjects with a CGI-S score of 1 or 2: score of 1=Normal; score of 2=Borderline ill</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of improvement as measured by the Clinical Global Impression - Improvement scale (CGI-I) for ADHD</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>CGI-I score by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate of improvement as measured by the categorical CGI-I Responder Rate (CGI-I score of 1 or 2)</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Percentage of subjects with CGI-I score of 1 or 2; score of 1 = Very much improved; score of 2 = Much improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety symptoms as measured by the Generalized Anxiety Disorder 7-Item scale (GAD-7)</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Change from baseline in the GAD-7 total score by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician-rated ADHD symptoms as measured by the AISRS subscales of Inattention and Hyperactivity/Impulsivity</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Change from baseline in the AISRS Inattention subscale score and Hyperactivity/Impulsivity subscale scores by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician response rate of ADHD symptom reduction as measured by the 50% responder rate in Adult ADHD Investigator Symptom Rating Scale (AISRS total score)</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>AISRS 50% responder rate (defined as the percentage of subjects with a ≥ 50% reduction in the CFB AISRS total score) by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician response rate of ADHD symptom reduction as measured by the 30% responder rate in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>AISRS 30% responder rate (defined as the percentage of subjects with a ≥ 30% reduction in the CFB AISRS total score) by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functioning as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A; Self Report)</measure>
    <time_frame>4 weeks - 8 weeks</time_frame>
    <description>Change from Baseline in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A; Self Report) T-score by visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspects of executive function and problems of self-regulation as measured by the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A; Self Report) Summary Index Scales and subscales</measure>
    <time_frame>2 weeks - 8 weeks</time_frame>
    <description>Change from baseline in the BRIEF-A T-score by each Summary Index Scale and subscale by visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Attention-Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Open-Label Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPN-812</intervention_name>
    <description>SPN-812 200 to 600 mg</description>
    <arm_group_label>Open-Label Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a male or female who completed Study 812P306 and opt/consent to participate in the
             study if approved by PI.

          2. Continues to be medically healthy with clinically normal laboratory profiles, vital
             signs, and electrocardiograms (ECGs), in the opinion of the Investigator, as assessed
             at Visit 1.

          3. Is able to read and understand the Informed Consent Form (ICF).

          4. Has signed the ICF.

          5. Is willing and able to attend study appointments within specified time windows.

          6. Is a female of childbearing potential (FOCP) who is either sexually inactive
             (abstinent) or, if sexually active, agrees to use one of the following acceptable
             birth control methods beginning at least 30 days prior to the first dose of SM and
             throughout the study:

               1. Simultaneous use of male condom and intra-uterine contraceptive device placed at
                  least 4 weeks prior to first SM administration

               2. Surgically sterile male partner

               3. Simultaneous use of male condom and diaphragm with spermicide

               4. Established hormonal contraceptive Females are considered not to be of
                  childbearing potential if they are either post-menopausal (amenorrhea for at
                  least 2 years and serum follicle stimulating hormone [FSH] level of &gt;40 IU/L) or
                  permanently sterilized (e.g., bilateral tubal ligation, hysterectomy, bilateral
                  oophorectomy for 6 months minimum prior to their Visit 1).

          7. Is a male who:

               1. Agrees to use 2 methods of contraception in combination if his female partner is
                  of childbearing potential; this combination of contraceptive methods must be used
                  from Visit 1 to ≥ 1 month after the last dose of SM, OR;

               2. Has been surgically sterilized prior to Visit 1.

        Exclusion Criteria:

          1. Is currently participating in another clinical trial other than Study 812P306.

          2. Has any current psychiatric disorder per Diagnostic and Statistical Manual of Mental
             Disorders - 5th Edition (DSM-5) criteria other than ADHD with the following
             exceptions: ADHD is primary diagnoses with comorbidity/secondary diagnoses of major
             depression disorder (MDD), nicotine dependence, social anxiety disorder, generalized
             anxiety disorder, or phobias.

          3. Current diagnosis of significant systemic disease and/or of a major psychiatric or
             neurological disorder, including history or family history of seizures or seizure-like
             disorders.

          4. Current evidence of suicidality (suicidal thoughts or behaviors).

          5. Female subjects who are pregnant, lactating and/or sexually active and not agreeing to
             use one of the acceptable birth control methods throughout the study.

          6. Has a positive result on urine drug screen at Visit 1.

          7. Use of prohibited concomitant medications including known CYP1A2 substrates (e.g.,
             theophylline, melatonin) at the Visit 1 for the duration of the study.

          8. Has a clinical laboratory value, vital sign value or ECG result at Visit 1 that is
             considered to be clinically significant in the opinion of the Investigator.

          9. Has one or more clinical laboratory test values outside the reference range at Visit 1
             that, in the opinion of the Investigator, are clinically significant, or any of the
             following:

               1. Serum creatinine &gt; 1.5 times the upper limit of normal (ULN);

               2. Serum total bilirubin &gt; 1.5 times ULN;

               3. Serum alanine aminotransferase or aspartate aminotransferase &gt; 2 times ULN.

         10. Has any of the following cardiology findings at Visit 1:

               1. Abnormal ECG that is, in the Investigator's opinion, clinically significant;

               2. PR interval &gt; 220 ms;

               3. QRS interval &gt; 130 ms;

               4. QTcF interval &gt; 450 ms (for men) or &gt; 470 ms (for women) (QT corrected using
                  Fridericia's method);

               5. Second- or third-degree atrioventricular block;

               6. Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to
                  be clinically significant.

         11. Any reason that, in the opinion of the Investigator, would prevent the subject from
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Schwabe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph T Hull, PhD</last_name>
    <phone>240-403-5324</phone>
    <email>jhull@supernus.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lily Makannah</last_name>
    <phone>240.403.5655</phone>
    <email>lmakannah@supernus.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South California Research LLC</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Zhang</last_name>
      <phone>424-284-3171</phone>
      <email>julie@scrstudies.com</email>
    </contact>
    <investigator>
      <last_name>Brock H Summers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Lendennie</last_name>
      <phone>714-799-7799</phone>
      <email>alyssalendennie@cnstrial.com</email>
    </contact>
    <investigator>
      <last_name>David Wallling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Henry</last_name>
      <phone>714-827-7627</phone>
      <email>mhenry@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Rosenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>My-Linh Tong</last_name>
      <phone>949-752-7910</phone>
      <email>mtong@priresearch.com</email>
    </contact>
    <investigator>
      <last_name>Nader Oskooilar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Research Institue for Clinical Research</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Patrick</last_name>
      <phone>951-374-1190</phone>
      <email>kpatrick@artemis-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Musikanth</last_name>
      <phone>858-278-3647</phone>
      <phone_ext>305</phone_ext>
      <email>mmusikanth@artemis-research.com</email>
    </contact>
    <investigator>
      <last_name>Eric Chavez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artemis Institute for Clinical Rearch</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Earle Bartoleme</last_name>
      <phone>760-266-4144</phone>
      <email>ebartolome@artemis-research.com</email>
    </contact>
    <investigator>
      <last_name>Stacey Layle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Network LLC</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Caces</last_name>
      <phone>310-523-4200</phone>
    </contact>
    <investigator>
      <last_name>Armen Goejian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulfcoast Research Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Corbett</last_name>
      <phone>239-561-0009</phone>
      <email>meghan@gulfcoastclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Zaheer Aslam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yadira Lugo</last_name>
      <phone>954-990-7649</phone>
      <phone_ext>137</phone_ext>
      <email>Yadira.lugo@rcatrials.com</email>
    </contact>
    <investigator>
      <last_name>Howard Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandita Joshi Jones, MD</last_name>
      <phone>904-281-5757</phone>
      <email>njoshijones@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Garner</last_name>
      <phone>863-940-2087</phone>
      <phone_ext>1508</phone_ext>
    </contact>
    <investigator>
      <last_name>Marlene Hart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center, LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marraffino, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Symone Ryner</last_name>
      <phone>386-775-7627</phone>
      <email>sryner@mrgcf.com</email>
    </contact>
    <investigator>
      <last_name>Adely Thebaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Klipper</last_name>
      <phone>407-425-5100</phone>
      <email>rklipper@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Molphus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Linda Harper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33634</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loletta Smith</last_name>
      <phone>813-877-8839</phone>
      <email>lsmith@meridienresearch.net</email>
    </contact>
    <investigator>
      <last_name>Deborah Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riesenberg, MD</last_name>
      <phone>404-881-5800</phone>
      <email>rriesenberg@acmr.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimball Johnson, MD</last_name>
      <phone>404-537-1281</phone>
      <email>drjohnson@iresearchatlanta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Psych Atlanta</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Schuck</last_name>
      <phone>770-422-2846</phone>
      <email>gayle@nbmedicine.com</email>
    </contact>
    <investigator>
      <last_name>Michael D Banov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Associates</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glynis Murphy</last_name>
      <phone>913-438-8221</phone>
      <email>research@murphyclinic.com</email>
    </contact>
    <investigator>
      <last_name>William Murphy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Charles Psychiatric Associates Midwest Research Center</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greg Mattingly, MD</last_name>
      <phone>636-946-8032</phone>
      <email>drmattingly@midwestresearchgroup.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alivation Research, LLC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Duffy, MD</last_name>
      <phone>402-817-2235</phone>
      <email>drduffy@premierpsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yurie Dean</last_name>
      <phone>702-527-7401</phone>
      <email>ydean@altearesearch.com</email>
    </contact>
    <investigator>
      <last_name>Jelena Kunovac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Psychiatry and Behavioral Medicine, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Kabins</last_name>
      <phone>702-838-0742</phone>
      <email>jordanckabins@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ann Childress</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassman Research Institute</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Varney</last_name>
      <phone>856-753-7335</phone>
      <phone_ext>768</phone_ext>
      <email>nvarney@hritrials.com</email>
    </contact>
    <investigator>
      <last_name>Steve Glass</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Emotional Fitness</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayon Choe</last_name>
      <phone>856-857-9500</phone>
      <phone_ext>19</phone_ext>
      <email>kchoe@cfef.com</email>
    </contact>
    <investigator>
      <last_name>Leon Rosenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hassmann Research Institute</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Hassman, DO</last_name>
      <phone>856-452-9901</phone>
      <phone_ext>818</phone_ext>
      <email>hhassman@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princeton Medical Institute</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rima Kotak</last_name>
      <phone>609-921-3555</phone>
      <email>rkotak@gminstitutes.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Apter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bioscience Research</name>
      <address>
        <city>Mount Kisco</city>
        <state>New York</state>
        <zip>10549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supritha Gowda</last_name>
      <phone>914-385-0200</phone>
      <email>sgowda@bioscienceresearchllc.com</email>
    </contact>
    <investigator>
      <last_name>David Krakow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medical Research Network LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10128r</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Donahue</last_name>
      <phone>212-595-5012</phone>
      <email>SDonahue@MedicalResearchNetwork.com</email>
    </contact>
    <investigator>
      <last_name>Micheal Liebowitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paradigm Research Professionals</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Novey</last_name>
      <phone>405-286-2104</phone>
      <email>angela@researchok.com</email>
    </contact>
    <investigator>
      <last_name>Courtney Nixon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Byrd</last_name>
      <phone>901-843-1045</phone>
      <email>lbyrd@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Valerie Arnold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin P.C.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divyansu Patel, MD</last_name>
      <phone>512-382-6661</phone>
      <email>dpatel@clin-edge.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>FutureSearch Trials of Dallas, LLP</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Caldwell</last_name>
      <phone>214-369-2600</phone>
      <email>jordanc@fstrials.com</email>
    </contact>
    <investigator>
      <last_name>Michael Downing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Katic, MD</last_name>
      <phone>713-527-8839</phone>
      <email>akatic@houstonclinitrials.com</email>
    </contact>
    <contact_backup>
      <last_name>M</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of the Woodlands</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marshall Lucas, MD</last_name>
      <phone>832-616-2674</phone>
      <email>mlucasmd@woodlandpsych.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trials</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan</last_name>
      <phone>425-453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

